Abstract
GEN EdgeVol. 5, No. 1 GEN EdgeDerisking Genetic Medicines with NeuBase and Ring TherapeuticsThese two preclinical biotech companies are establishing diverging platforms to address safety in gene editing and nucleic acid therapeuticsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:6 Jun 2023https://doi.org/10.1089/genedge.5.1.82AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Derisking Genetic Medicines with NeuBase and Ring Therapeutics.GEN Edge.Jan 2023.419-423.http://doi.org/10.1089/genedge.5.1.82Published in Volume: 5 Issue 1: June 6, 2023PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
